IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against...
Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children...
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in...
Former Medicine Development Leader for MAGE-A4+ Autologous Cell Therapies Will Support Advancement of CDR-Life’s M-gager® Solid Tumor TherapiesZÜRICH, Switzerland, Aug....
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — —...
Dr. Turgeon is an esteemed Clinical Professor at University of Michigan Health and clinical translational researcher with specific research interest...
The Digital LightCycler System is a next-generation digital PCR system that helps clinical researchers better understand the nature of a...
LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty...
Preparations for Tollovir™ Phase 2 Trial Extension to Support EUA Filing Now Complete Preparations for Tollovid™ Phase 2 Trial in...
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE...
ALLEN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Atrion Corporation (Nasdaq ATRI) today announced an increase in its quarterly cash...
Two-decade industry veteran joined Elevar as VP of finance in January Elevar Therapeutics Names Wade Smith Chief Financial Officer Wade...
JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer...
Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 millionReduction in expenses...
DCBY02 to be assessed in patients with advanced or metastatic solid tumors across dose-escalation and dose-expansion parts of a Phase...
MUNICH, Germany, Aug. 22, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage precision psychiatry...
MIAMI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Expands Trial to 17 U.S. Sites and 25 Locations Initiation of All Anticipated U.S. Trial Sites Largely Completed HOUSTON, Aug. 22,...
PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023 FREMONT, CA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via...